97859-49-9

Usage

Uses

Used in Pharmaceutical Synthesis:
(R)-5-(hydroxyMethyl)oxazolidin-2-one is used as a key intermediate in the synthesis of various pharmaceuticals and biologically active compounds. Its unique structure and reactivity contribute to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Production:
(R)-5-(hydroxyMethyl)oxazolidin-2-one is utilized as a crucial component in the production of agrochemicals. Its incorporation aids in the creation of effective compounds for agricultural use, enhancing crop protection and yield.
Used in Fine Chemicals Industry:
(R)-5-(hydroxyMethyl)oxazolidin-2-one is used as a building block in the synthesis of fine chemicals. Its presence in these chemical reactions allows for the production of high-quality specialty chemicals used across various industries.

Upstream product

• 113420-80-7 Acetic acid (S)-2-oxo-oxazolidin-5-ylmethyl ester 
• 61278-21-5 (S)-3-Amino-1,2-propanediol 
• 105-58-8 Diethyl carbonate 
• 7517-99-9 5-hydroxymethyl-2-oxazolidinone 
• 852805-35-7 (S)-5-(4-methoxyphenoxymethyl)-1,3-oxazolidin-2-one 
• 113420-80-7 Acetic acid (R)-2-oxo-oxazolidin-5-ylmethyl ester 
• 66211-46-9 (R)-3-amino-1,2-propanediol 
• 641617-22-3 (R)-3-[N-(benzyloxycarbonyl)amino]-1,2-propanediol 
• 274264-54-9 (5R)-5-[(benzyloxy)methyl]-1,3-oxazolidin-2-one 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 169048-84-4 (R)-2-oxo-oxazolidine-5-carboxylic acid benzyl ester 
• 330555-60-7 (S)-5-triphenylmethoxymethyl-1,3-oxazolidin-2-one 
• 112663-80-6 (S)-2-oxazolidinone-5-carboxylic acid benzyl ester 

Downstream Products

• 402718-20-1 ((5R)-2-oxo-1,3-oxazolidin-5-yl)methyl 2-nitrobenzenesulfonate 
• 352524-57-3 (R)-5-(((tert-butyldiphenylsilyl)oxy)methyl)oxazolidin-2-one 
• 109794-69-6 (R)-(2-oxo-1,3-oxazolidin-5-yl)methyl 4-methylbenzenesulfonate 
• 109794-68-5 (S)-(2-oxo-1,3-oxazolidin-5-yl)methyl 4-methylbenzenesulfonate 

Relevant academic research and scientific papers

MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS

Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidases SpsB and/or LepB, an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

QUINAZOLINE COMPOUND FOR EGFR INHIBITION

Disclosed is a novel quinazoline compound. Specifically, disclosed are a compound represented by the formula (I) and a pharmacologically acceptable salt.

Inhibition of 3-phosphoglycerate dehydrogenase (PHGDH) by indole amides abrogates de novo serine synthesis in cancer cells

Cancer cells reprogram their metabolism to support growth and to mitigate cellular stressors. The serine synthesis pathway has been identified as a metabolic pathway frequently altered in cancers and there has been considerable interest in developing pharmacological agents to target this pathway. Here, we report a series of indole amides that inhibit human 3-phosphoglycerate dehydrogenase (PHGDH), the enzyme that catalyzes the first committed step of the serine synthesis pathway. Using X-ray crystallography, we show that the indole amides bind the NAD+ pocket of PHGDH. Through structure-based optimization we were able to develop compounds with low nanomolar affinities for PHGDH in an enzymatic IC50 assay. In cellular assays, the most potent compounds inhibited de novo serine synthesis with low micromolar to sub-micromolar activities and these compounds successfully abrogated the proliferation of cancer cells in serine free media. The indole amide series reported here represent an important improvement over previously published PHGDH inhibitors as they are markedly more potent and their mechanism of action is better defined.

METHOD FOR PREPARING OXAZOLIDINONE INTERMEDIATE

The invention relates to a method for preparing an oxazolidinone intermediate. Specifically, a synthesis procedure for the intermediate comprises: directly performing a “one-pot” reaction on a compound I, compound J or compound L without performing isolation, wherein a salt of a compound K is selected from a hydrochloride, sulfate, malate, tartrate, p-toluenesulfonate, or lactate, and wherein the symbol * in a compound indicates an atom of an R-type chirality or an S-type chirality or a racemate thereof.

COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS

Compounds of formula (I), pharmaceutically acceptable salts thereof, and uses of the compounds of formula (I) for treating bacterial infections are disclosed.

NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME

Compounds are provided which are phosphonate and phosphinate activators and thus are useful in treating diabetes and related diseases and have the structure wherein is a heteroaryl ring; R4 is —(CH2)n-Z-(CH2)m—PO(OR7)(OR8), —(CH2)nZ-(CH2)m—PO(OR7)Rg, —(CH2)n-Z-(CH2)m—OPO(OR7)Rg, —(CH2)nZ—(CH2)m—OPO(R9)(R10), or —(CH2)nZ—(CH2)m—PO(R9)(R10);R5 and R6 are independently selected from H, alkyl and halogen;Y is R7(CH2)s or is absent; andX, n, Z, m, R4, R5, R6, R7, and s are as defined herein; or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.

Lipase-mediated resolution of 3-hydroxy-4-trityloxybutanenitrile: synthesis of 2-amino alcohols, oxazolidinones and GABOB

Lipase-mediated kinetic resolution of 3-hydroxy-4-trityloxybutanenitrile gave the (S)-alcohol and (R)-acetate in good yields and high enantioselectivities. The resolution using Pseudomonas cepacia lipase (Burkholderia cepacia) immobilized on modified cera

Antibacterial agents

Compounds of formula I and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula I as well as pharmaceutically acceptable compositions comprising compounds of formula I. Compounds of formula I as disclosed herein can be used in a variety of applications, including using the invention compounds to treat bacterial infections.

New chemoenzymatic pathway for β-adrenergic blocking agents

The lipase mediated kinetic resolution of pharmaceutically important β-hydroxy nitriles is described in high enantiomeric excesses and good yields. Some of the chiral β-hydroxy nitriles have been employed in the synthesis of β-adrenergic blocking agents such as propranolol, alprenolol and moprolol. This protocol has also been extended for the enantiopure preparation of 5-(4-tosyloxymethyl)-1,3-oxazolidine-2-one and 3-hydroxy-4-tosyloxybutanenitrile, chiral intermediates of high synthetic value.

ANTIBACTERIAL AGENTS

Compounds of formula I and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula I as well as pharmaceutically acceptable compositions comprising compounds of formula I. Compounds of formula I as disclosed herein can be used in a variety of applications including use as antibacterial agents.